Malignant tumors of the adrenal cortex;Maligne tumoren der nebennierenrinde

Internist

Volumn 43, Issue 2, 2002, Pages 186-195

  Allolio, Bruno ^a   Fassnacht, M ^b   Arlt, W ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; MITOTANE;

ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; ADRENAL SCINTISCANNING; CANCER LOCALIZATION; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; REVIEW; TREATMENT INDICATION;

ADRENAL CORTEX; ADRENAL GLAND NEOPLASMS; BIOPSY; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; HUMANS; NEOPLASM STAGING; PARANEOPLASTIC ENDOCRINE SYNDROMES; SURVIVAL RATE;

EID: 0036970970     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-001-0509-1     Document Type: Review

References (40)

1. Schteingart DE, Homan D (2001) Management of adrenal cancer. In: Margioris AN, Chrousos GP (eds) Adrenal disorders. Humana, Totowa, New Jersey, pp 231-248
2. Wajchenberg B, Albergaria PM, Medonca B et al. (2000) Adrenocortical carcinoma: clinical and laboratory observations. Cancer 88: 711-736
3. Reincke M (2001) Adrenocortical tumors and oncogenes. In: Margioris AN, Chrousos GP (eds) Adrenal disorders. Humana, Totowa, New Jersey, pp 219-30
4. Beuschlein F, Fassnacht M, Klink A, Allolio B, Reincke M (2001) ACTH-receptor expression, regulation and role in adrenocortial tumor formation. Eur J Endocrinol 144: 199-206
5. Dohna M, Reincke M, Mincheva A, Allolio B, Solinas-Toldo S, Lichter P (2000) Adrenocortical carcinoma is characterized by a high frequency of chromosomal gains and high-level amplifications. Genes Chromosomes Cancer 28: 145-52
6. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B (1995) Incidentally discovered adrenal masses. Endocr Rev 16: 460-484
7. Mantero F, Terzolo M, Arnaldi G et al. (2000) A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 85: 637-644
8. Allolio B (2001) Adrenal incidentalomas. In: Margioris AN, Chrousos GP (eds) Adrenal disorders. Humana, Totowa, New Jersey, pp 249-261
9. MacFarlane DA (1958) Cancer of the adrenal cortex: the natural history, prognosis and treatment in the study of fifty cases. Ann R Coll Surg Engl 109: 613-618
10. Sullivan M, Boileau M, Hodges CV (1978) Adrenal cortical carcinoma. J Urol 120: 660-665
11. Hurter AM, Kayhoe DE (1966) Adrenal cortical carcinoma. Clinical features of 138 patients. Am J Med 41: 572-580
12. King DR, Lack EE (1979) Adrenal cortical carcinoma: A clinical and pathologic study of 49 cases. Cancer 44: 239-244
13. Luton JP, Cerdas S, Billaud L et al. (1990) Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322: 1195-1201
14. Korobkin M, Lombardi TJ, Aisen AM et al. (1995) Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR imaging. Radiology 197: 411-418
15. Saeger W (2000) Histopathological classification of adrenal tumours. Eur J Clin Invest 30 (Suppl): 58-62
16. Saeger W, Fassnacht M, Beuschlein F et al. (2001) Ex-vivo biopsies of adrenal lesions: morphology of 231 cases. Exp Clin Endocrinol Diabetes 109: v076
17. Mody MK, Kazerooni EA, Korobkin M (1995) Percutaneous CT-guided biopsy of adrenal masses: immediate and delayed complications. J Comput Assist Tomogr 19: 434-439
18. Nies C (2000) Chirurgische Anatomie, konventionelle und minimalinvasive Zugänge zur Nebenniere. In: Siewert JR, Harder F, Rothmund M (Hrsg) Praxis der Viszeralchirurgie. Springer, Berlin Heidelberg New York Tokio, S 349-361
19. Icard P, Louvel A, Chapuis Y (1992) Survival rates and prognostic factors in adrenocortical carcinoma. World J Surg 16: 753-758
20. Bates SE, Shieh CY, Mickley LA, Dichek HL, Gazdar A, Loriaux DL, Fojo AT (1991) Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab 73: 18-29
21. Lubitz JA, Freeman L, Okun R (1973) Mitotane use in inoperable adrenal cortical carcinoma. JAMA 223: 1109-1112
22. Hogan TF, Citrin DL, Johnson BM, Nakamura S, Davis TE, Borden EC (1978) o,p′-DDD (mitotane) therapy of adrenal cortical carcinoma: Observations on drug dosage, toxicity, and steroid replacement. Cancer 42: 2177-2181
23. Boven E, Vermorken JB, van Slooten H, Pinedo HM (1984) Complete response of metastasized adrenal cortical carcinoma with o,p′-DDD. Case report and literature review. Cancer 53: 26-29
24. van Slooten H, Moolenaar AJ, van Seters AR Smeenk D (1984) The treatment of adrenocortical carcinoma with o,p′-DDD: Prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 20: 47-53
25. Freeman DA (1986) Steroid hormone-producing tumors in man. Endocr Rev 7: 204-220
26. Venkatesh S, Hickey RC, Sellin RV, Fernandez JF, Samaan NA (1989) Adrenal cortical carcinoma. Cancer 64: 765-769
27. Haak HR, van Seters AP, Moolenaar AJ (1990) Mitotane therapy of adrenocortical carcinoma. N Engl J Med 323: 758
28. Wooten MD, King DK (1993) Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 72: 3145-3155
29. Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ, Krans HM (1994) Optimal treatment of adrenocortical carcinoma with mitotane: Results in a consecutive series of 96 patients. Br J Cancer 69: 947-951
30. Kasperlik-Zaluska AA, Migdalska BM, Makowska AM (1996) Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Two years later. Cancer 78: 1520-1521
31. van Seters AP, Moolenaar AJ (1991) Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol (Copenh) 124: 526-533
32. Khan TS, Imam H, Juhlin C et al.(2000) Streptozocin and o,p′DDD in the treatment of adrenocortical cancer patients: Long-term survival in its adjuvant use. Ann Oncol 11: 1281-1287
33. Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L (1998) Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 83: 2194-2200
34. Bonacci R, Gigliotti A, Baudin E et al. (1998) Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Reseau Comete INSERM. Br J Cancer 78: 546-549
35. Allolio B, Arlt W, Reincke M (1996) Medical treatment of Cushing's syndrome. In: von Werder K, Fahlbusch R (eds) Pituitary adenomas: From basic research to diagnostic and therapy. Elsevier, Amsterdam, pp 223-229
36. Contreras P, Rojas A, Biagini L, Gonzalez P, Massardo T (1985) Regression of metastatic adrenal carcinoma during palliative ketoconazole treatment. Lancet 2: 151-152
37. Schulte HM, Benker G, Reinwein D, Sippell WG, Allolio B (1990) Infusion of low dose etomidate: Correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 70: 1426-1430
38. Vierhapper H, Nowotny, Mostbeck G, Waldhausl W (1989) Effect of suramin in a patient with adrenocortical carcinoma. Lancet 1: 1207-1208
39. Flack MR, Pyle RG, Mullen NM et al. (1993) Oral gossypol in the treatment of metastatic adrenal cancer. J Clin Endocrinol Metab 76: 1019-1024
40. Arlt W, Reincke M, Siekmann L, Winkelmann W, Allolio B (1994) Suramin in adrenocortical cancer: Limited efficacy and serious toxicity. Clin Endocrinol (Oxf) 41: 299-307